Aug 28, 2013

Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer

The Journal of Clinical Endocrinology and Metabolism
Marina N NikiforovaYuri E Nikiforov

Abstract

Next-generation sequencing (NGS) allows for high-throughput sequencing analysis of large regions of the human genome. We explored the use of targeted NGS for simultaneous testing for multiple mutations in thyroid cancer. A custom panel (ThyroSeq) was designed to target 12 cancer genes with 284 mutational hot spots. Sequencing was performed to analyze DNA from 228 thyroid neoplastic and nonneoplastic samples including 105 frozen, 72 formalin-fixed, and 51 fine-needle aspiration samples representing all major types of thyroid cancer. Only 5-10 ng of input DNA was sufficient for successful analysis of 99.6% of samples. The analytical accuracy for mutation detection was 100% with the sensitivity of 3%-5% of mutant allele. ThyroSeq DNA assay identified mutations in 19 of 27 of classic papillary thyroid carcinomas (PTCs) (70%), 25 of 30 follicular variant PTCs (83%), 14 of 18 conventional (78%) and 7 of 18 oncocytic follicular carcinomas (39%), 3 of 10 poorly differentiated carcinomas (30%), 20 of 27 anaplastic (ATCs) (74%), and 11 of 15 medullary thyroid carcinomas (73%). In contrast, 5 of 83 benign nodules (6%) were positive for mutations. Most tumors had a single mutation, whereas several ATCs and PTCs demonstrated two or three mu...Continue Reading

  • References
  • Citations205

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations205

Citations

Mentioned in this Paper

TP53 gene
Gene Expression Regulation, Neoplastic
Histiocytoid Cardiomyopathy
Fine-needle Biopsy
Pyotraumatic Dermatitis
BRAF protein, human
GNAS gene
Nodule
Formalin
Beta catenin

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.